Compare Figs Inc (FIGS) vs Viatris Inc (VTRS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Figs Inc vs Viatris Inc — how do they compare? Figs Inc trades at $15.78 (market cap $2.49B), while Viatris Inc trades at $17.64 (market cap $20.03B). The key difference: Viatris Inc is far larger — about 8× Figs Inc's market cap, and Viatris Inc pays a 2.75% dividend while Figs Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Figs Inc for 33 Days and Viatris Inc for 57 Days on average.
| FIGS | VTRS | |
|---|---|---|
Market Cap | $2.49B | $20.03B |
Volume | 5,964,311 | 14,109,977 |
Sector | Consumer Cyclical | Health |
52-Week High | $17.12 | $18.27 |
52-Week Low | $6.90 | $9.74 |
Typical Hold Time | 33 Days | 57 Days |
Enterprise Value | $2.25B | $32.15B |
Dividend Yield | — | 2.75% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FIGS stock trades at $14.98, up 6.54% in the last session, with a bullish technical signal and strong earnings beats in recent quarters. Revenue grew to $631.10M in 2025, with net income reaching $34.25M, and the company has raised its 2026 outlook. The stock shows momentum with a consensus price target of $18.00, indicating potential upside from current levels.
The outlook for FIGS is positive, driven by accelerating revenue growth, expanding international sales, and improving margins. Key risks include its premium valuation and execution challenges in sustaining growth. Analyst sentiment is predominantly bullish, supporting a favorable investment case for growth-oriented investors.
Viatris (VTRS) trades at $17.44, down 0.29% on the day, with a bullish technical signal from moving averages and oversold short-term RSI. The company reported three consecutive quarterly earnings beats in 2026, with Q2 EPS of $0.69 beating estimates by 14.8%. Revenue for 2025 was $14.3B, though net income was negative $3.51B, reflecting margin pressure. Positive news includes a new drug approval in Japan and recognition as a top employer.
The outlook is mixed: strong cash flow generation and deleveraging support shareholder returns via dividends and buybacks, but profitability challenges and high debt levels pose risks. Analyst consensus is a 'Buy' with a $22.17 price target, implying 27% upside. Investment appeal hinges on execution of pipeline growth and margin improvement amid competitive and pricing pressures in the generics market.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Figs Inc
FIGS Inc is a healthcare apparel company. It offers more fitted scrubs for men and women made of its proprietary fabric FIONx, which provides four-way stretch and has anti-odor, anti-wrinkle, and moisture-wicking properties.
Read more on FIGS →About Viatris Inc
Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →
